ArticleFrontiers in immunology2026
Cascade of opportunistic infections in focal segmental glomerulosclerosis under dual immunosuppressive therapy: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Focal segmental glomerulosclerosis (FSGS) is a heterogeneous glomerular disease frequently treated with high-dose glucocorticoids and calcineurin inhibitors, which can markedly increase susceptibility to opportunistic infections. Case presentation: A 53-year-old previously healthy male presented with nephrotic syndrome and was diagnosed with FSGS on renal biopsy, for which he received high-dose prednisolone followed by cyclosporine. During dual immunosuppressive therapy, he developed sequential opportunistic infections, beginning with Conclusions: This case illustrates how prolonged combined corticosteroid and calcineurin inhibitor therapy in FSGS can precipitate a cascade of severe opportunistic infections, emphasizing the need for early pathogen-specific prophylaxis, vaccination, systematic infection surveillance, and dynamic reassessment of cumulative immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.